Actively Recruiting
Local Liver Treatment for Multi-organ Colorectal Cancer Metastases
Led by Anhui Provincial Hospital · Updated on 2024-06-10
130
Participants Needed
6
Research Sites
208 weeks
Total Duration
On this page
Sponsors
A
Anhui Provincial Hospital
Lead Sponsor
F
First Affiliated Hospital of Wannan Medical College
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study was to investigate the effect of only local radical treatment of liver metastases combined with systematic treatment in the treatment of patients with multiple organ metastases of colorectal cancer, whether it can benefit the prognosis and explore the risk factors related to the prognosis.
CONDITIONS
Official Title
Local Liver Treatment for Multi-organ Colorectal Cancer Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, 18-80 years of age
- Willing to participate and able to comply with study requirements
- Primary colorectal tumors that can be completely removed or have been removed and confirmed as colorectal cancer
- Diagnosis of liver and extrahepatic metastases confirmed by CT or MRI, with extrahepatic metastases stable and controllable
- Receiving only first- or second-line systemic therapy
- Eligible for radical local treatment after evaluation, meeting criteria for hepatectomy or ablation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Life expectancy of at least 3 months
- Child-Pugh score of 7 or less
- Laboratory tests within specified normal ranges (including blood counts, liver and kidney function, coagulation)
You will not qualify if you...
- Patients with only liver metastasis
- History of hepatic encephalopathy or liver transplantation
- Presence of brain metastases
- Pregnant or breastfeeding women
- History of other malignant tumors unless disease-free for at least 5 years
- Recent acute cardiovascular or cerebrovascular events or poorly controlled cardiovascular diseases
- Severe heart failure (NYHA class 3-4) or low heart function (LVEF < 50%)
- Uncontrolled high blood pressure or history of hypertensive crisis
- Severe uncontrolled infections
- Respiratory failure with low oxygen or high carbon dioxide levels
- Large amounts of ascites or malignant ascites
- Blood clotting disorders with bleeding risk
- Recent major surgery, severe injury, or unhealed wounds
- History of drug abuse or mental disorders affecting participation
- Other serious diseases or conditions judged by investigators to affect safety or study completion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
The First People's Hospital of Chu Zhou
Chuzhou, Anhui, China, 233100
Actively Recruiting
2
Fuyang Cancer Hospital
Fuyang, Anhui, China, 236000
Actively Recruiting
3
Anhui province hospital
Hefei, Anhui, China, 230000
Actively Recruiting
4
Ma'anshan People's Hospital
Ma’anshan, Anhui, China, 243000
Actively Recruiting
5
The First Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China, 241000
Actively Recruiting
6
The Second People's Hospital of Wuhu
Wuhu, Anhui, China, 241000
Actively Recruiting
Research Team
J
Ji-Zhou Wang, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here